Targeting brain metastases in ALK-rearranged non-small-cell lung cancer

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages e510-e521

  Zhang, Isabella ^a   Zaorsky, Nicholas G ^b   Palmer, Joshua D ^c   Mehra, Ranee ^b   Lu, Bo ^c  

^a Northwell Health   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 4 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO] 1,3,5 TRIAZINE; 5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; 6 AMINO 5 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] N [4 (4 METHYL 1 PIPERAZINYLCARBONYL)PHENYL] 3 PYRIDAZINECARBOXAMIDE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BRIGATINIB; CEP 28122; CERITINIB; CRIZOTINIB; ENTRECTINIB; LORLATINIB; TSR 011; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ALK GENE; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; CANCER GROWTH; CANCER RADIOTHERAPY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; MENINGEAL METASTASIS; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR MICROENVIRONMENT; ADJUVANT THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHENOTYPE; SECONDARY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PHENOTYPE; PROTEIN KINASE INHIBITORS; RADIOTHERAPY, ADJUVANT; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84953874716     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00013-3     Document Type: Review

References (97)

1. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655-661.
2. Wolburg H, Lippoldt A Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38:323-337.
3. Butt AM, Jones HC, Abbott NJ Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990, 429:47-62.
4. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37:13-25.
5. Abbott NJ, Rönnbäck L, Hansson E Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53.
6. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000, 26:449-462.
7. Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 2000, 100:323-331.
8. Deeken JF, Löscher W The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007, 13:1663-1674.
9. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
10. Mossé YP, Wood A, Maris JM Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009, 15:5609-5614.
11. Shaw AT, Solomon B Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011, 17:2081-2086.
12. Yang T, Liu H, Chen J EML4-ALK fusion gene in lung cancer and its biological function. Zhongguo Fei Ai Za Zhi 2012, 15:112-116. (in Chinese).
13. Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012, 118:4502-4511.
14. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
15. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012, 17:1351-1375.
16. Kulig KWY, Iyer S, Yang P Predictive and prognostic value of ALK gene rearrangement in non-small cell lung cancer. Epidemiology 2014, 4:146.
17. Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012, 7:90-97.
18. Sun JM, Lira M, Pandya K, et al. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer 2014, 83:259-264.
19. Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 2014, 32:2780-2787.
20. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664-672.
21. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999, 341:476-484.
22. Preusser M, Berghoff AS, Ilhan-Mutlu A, et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 2013, 80:278-283.
23. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
24. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
25. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011, 6:942-946.
26. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
27. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
28. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
29. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015, 33:1881-1888.
30. Solomon BFE, Felipe E, Blackhall FH, et al. Overall and intracranial (IC) efficacy results and time to symptom deterioration in PROFILE 2014: 1st line crizotinib vs. pemetrexed-platinum chemotherapy (PPC) in patients (PTS) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC). Ann Oncol 2014, 25(suppl 4):iv426-iv470.
31. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29:e443-e445.
32. Maillet D, Martel-Lafay I, Arpin D, Pérol M Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol 2013, 8:e30-e31.
33. Ahn HK, Han B, Lee SJ, et al. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer 2012, 76:253-254.
34. Riess JW, Nagpal S, Neal JW, Wakelee HA A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. J Natl Compr Canc Netw 2013, 11:389-394.
35. Falk AT, Poudenx M, Otto J, Ghalloussi H, Barrière J Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report. Lung Cancer 2012, 78:282-284.
36. Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?. Cancer Biol Ther 2012, 13:1376-1383.
37. Takeda M, Okamoto I, Nakagawa K Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 2013, 8:654-657.
38. Pop O, Pirvu A, Toffart AC, Moro-Sibilot D Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol 2012, 7:e1-e2.
39. Kaneda H, Okamoto I, Nakagawa K Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J Thorac Oncol 2013, 8:e32-e33.
40. Kim YH, Ozasa H, Nagai H, et al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 2013, 8:e85-e86.
41. Hayashi H, Okamoto I, Tanizaki J, et al. Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement. J Clin Oncol 2014, 32:e122-e124.
42. Kinoshita Y, Koga Y, Sakamoto A, Hidaka K Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. BMJ Case Rep 2013, published online Sep 10, 2013. 10.1136/bcr-2013-200867.
43. Chun SG, Iyengar P, Gerber DE, Hogan RN, Timmerman RD Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. J Clin Oncol 2015, 33:e25-e26.
44. Gandhi L, Drappatz J, Ramaiya NH, Otterson GA High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 2013, 8:e3-e5.
45. Ajimizu H, Kim YH, Mishima M Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med Oncol 2015, 32:477.
46. Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015, 10:232-236.
47. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012, 7:1807-1814.
48. Chuan Tang S, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 2014, 134:1484-1494.
49. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739. the ALK Lung Cancer Study Group.
50. Shaw AT, Engelman JA Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:2537-2539.
51. Shaw AT, Mehra R, Tan DSW, et al. Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND-1 trial. Neuro Oncol 2014, 16(suppl 5):v39.
52. Kim D-W, Mehra R, Tan DSW, et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. Proc Am Soc Clin Oncol 2014, 32:8003. (abstr).
53. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
54. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014, 15:1119-1128.
55. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014, 74:1023-1028.
56. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
57. Inoue A, Nishio M, Kiura K, et al. One-year follow-up of a Phase I/II study of a highly selective ALK inhibitor CH542802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC). World Conference on Lung Cancer; Oct 27-31, 2013; Sydney, Australia.
58. Seto T, Hida T, Nakagawa K, et al. Anti-tumor activity of alectinib in crizotinib pre-treated ALK-rearranged NSCLC in JP28927 study. Ann Oncol 2014, 25(suppl 4):iv426-iv470.
59. Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. Proc Am Soc Clin Oncol 2013, 31:8031. (abstr).
60. Gettinger SN, Bazhenova L, Salgia R, et al. ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell cancer (NSCLC): updated efficacy and safety data. Ann Oncol 2014, 25(suppl 4):iv426-iv470.
61. Gettinger SN, Weiss GJ, Salgia R, et al. A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. Ann Oncol 2012, 23(suppl 9):4390. (abstr).
62. Rivera VM, Anjum R, Wang F, et al. Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of anaplastic lymphoma kinase (ALK). Cancer Res 2010, 70(suppl 8):3623. (abstr).
63. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 2014, 57:4720-4744.
64. Mori M, Ueno Y, Konagai S, et al. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther 2014, 13:329-340.
65. Konagai SFH, Sakagami H, Ueno Y, et al. ASP3026, a selective ALK inhibitor, shows anti-tumor activity in a mouse model xenografted with NCI-H2228 intracranially. Cancer Res 2013, 73(suppl 8):918. (abstr).
66. Lovly CM, Heuckmann JM, de Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011, 71:4920-4931.
67. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012, 7:382-385.
68. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013, 8:185-191.
69. Park S, Park TS, Choi CM, et al. Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements. Clin Lung Cancer 2015, published online Jan 10, 2015. 10.1016/j.cllc.2015.01.003.
70. Bearz A, Garassino I, Tiseo M, et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 2010, 68:264-268.
71. Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014, 20:1027-1034.
72. Lovly CM, Pao W Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012, 4:120ps2.
73. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17.
74. Giri S, Patel JK, Mahadevan D Novel mutations in a patient with ALK-rearranged lung cancer. N Engl J Med 2014, 371:1655-1656.
75. Ramalingam SS, Khuri FR Second-generation ALK inhibitors: filling the non "MET" gap. Cancer Discov 2014, 4:634-636.
76. Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014, 20:5686-5696.
77. Gaimor JF, Friboulet L, Katayama R, et al. Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). J Clin Oncol 2014, 32(suppl):8031. (abstr).
78. Gallegos Ruiz MI, Floor K, Roepman P, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008, 3:e0001722.
79. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013, 19:3068-3077.
80. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
81. Yang L, Li G, Zhao L, Pan F, Qiang J, Han S Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer. Tumour Biol 2014, 35:9759-9767.
82. Salphati L, Heffron TP, Alicke B, et al. Targeting the PI3K pathway in the brain-efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res 2012, 18:6239-6248.
83. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2005, 2:554-571.
84. Côté J, Savard M, Neugebauer W, Fortin D, Lepage M, Gobeil F Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors. Cancer Biol Ther 2013, 14:806-811.
85. Jain RK Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013, 31:2205-2218.
86. Jain RK Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
87. Jain RK Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
88. Jain RK Taming vessels to treat cancer. Sci Am 2008, 298:56-63.
89. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
90. Helmlinger G, Yuan F, Dellian M, Jain RK Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
91. Monje ML, Mizumatsu S, Fike JR, Palmer TD Irradiation induces neural precursor-cell dysfunction. Nat Med 2002, 8:955-962.
92. d'Avella D, Cicciarello R, Albiero F, et al. Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation. Neurosurgery 1992, 30:30-34.
93. Nicolson GL Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988, 7:143-188.
94. Mak KS, Gainor JF, Niemierko A, et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro-oncol 2015, 17:296-302.
95. Rubin P, Gash DM, Hansen JT, Nelson DF, Williams JP Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiother Oncol 1994, 31:51-60.
96. Mima T, Toyonaga S, Mori K, Taniguchi T, Ogawa Y Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation. Neurol Res 1999, 21:209-215.
97. Ou SH, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014, 25:415-422.